A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity,
 safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV
 suppressed subjects under nucleo(s)tide treatment.
Inclusion Criteria:

 -  Patients who, in the opinion of the investigator, can and will comply with the
 requirements of the protocol.

 -  Written informed consent obtained from the patient prior to performing any study
 specific procedure.

 -  A male or female between, and including, 18 and 65 years of age at the time of the
 first vaccination.

 -  Female patients of non-childbearing potential may be enrolled in the study.
 Non-childbearing potential is defined as hysterectomy, bilateral ovariectomy or
 post-menopause.

 -  Female patients of childbearing potential may be enrolled in the study if the patient:

 -  has practiced adequate contraception for 30 days prior to vaccination, and

 -  has a negative pregnancy test at Screening, and

 -  has agreed to continue adequate contraception from Screening until 12 weeks after
 completion of the vaccination series

 -  Male patients:

 -  with documented bilateral vasectomy and resultant azoospermia, bilateral
 orchiectomy or azoospermia, or

 -  who agree to practice abstinence from penile-vaginal intercourse (when this is
 their preferred and usual lifestyle) or use condoms from Screening until 12 weeks
 after completion of the vaccination series.

 -  Chronic Hepatitis B (CHB) patient, under and adherent to treatment with a
 nucleo(s)tide analogue with high barrier to resistance given as per approved
 label/dosage for at least 24 months.

 -  Documented medical history of Hepatitis B Virus.e Antigen (HBeAg)-negative CHB prior
 to onset of NA therapy.

 -  Documented HBV viral suppression as per local clinical diagnosis within the previous
 24 months AND at Screening test HBV DNA < 10 IU/mL. If no results are available, two
 Screening tests need to be performed at least 2 weeks apart. Small fluctuations of HBV
 DNA (≤ 10 x LLOQ; LLOQ defined by laboratory that performed testing) are allowed
 provided HBV DNA is < 10 IU/mL at Screening and was clearly not rising during the
 previous 24 months.

 -  Documented normal level of ALT as per local clinical diagnosis within the previous 24
 months AND at Screening test ALT < 48U/L. Small fluctuations of ALT (≤ 1.5 X ULN) are
 allowed provided ALT< 48 U/L at Screening. If no results are available, two Screening
 tests need to be performed at least 2 weeks apart. ULN are to be defined according to
 local laboratory reference range.

 -  No clinical diagnosis of cirrhosis (e.g. F4 by METAVIR scoring system or ≥ 6 by Ishak
 scoring system or FibroScan TE score > 12.5 kPa) within the previous 24 months.

 -  FibroScan Transient Elastography (TE) score < 9.6 kPa and FibroTest score < 0.59 at
 Screening. A patient with one of these parameters out of range, but having the liver
 biopsy within 12 months before screening that showed F0-2 by METAVIR scoring system or
 stage 0-4 by Ishak scoring system, can be included.

 -  HBsAg concentration > 50 IU/mL and anti-HBs negative at Screening.

 -  Anti-HBc positive at Screening.

 -  HBeAg-negative at Screening.

 Exclusion Criteria:

 -  Use of any investigational or non-registered product (drug or vaccine) other than the
 study vaccines during the period starting 30 days before the first dose of study
 vaccines (Day -29 to Day 1), or planned use during the study period.

 -  Any medical condition that in the judgment of the investigator would make
 intramuscular injection unsafe.

 -  Chronic administration of immunosuppressants (defined as more than 14 days in total)
 or other immune-modifying drugs (including but not limited to IFN) during the period
 starting six months prior to the first vaccine dose. For corticosteroids, this will
 mean prednisone ≥ 10 mg/day or equivalent. Inhaled and topical steroids are allowed.

 -  Administration of immunoglobulins and/or any blood products during the period starting
 3 months before the first dose of study vaccines or planned administration during the
 study period.

 -  Use of systemic cytotoxic agents, chronic antiviral agents or Chinese herbal medicines
 which, in the opinion of the investigator, may have activity against HBV within the
 previous 6 months prior to randomization into this study. Antiviral
 treatment/prevention for influenza or herpes simplex virus (HSV) is allowed.

 -  Administration of adenovirus/adenovector-based or MVA-based vaccine within the last 12
 months.

 -  Planned administration/administration of a vaccine not foreseen by the study protocol
 in the period starting 14 days before each dose and ending 30 days after each dose of
 vaccines, with the exception of influenza vaccine that may be given at any time except
 within a 7-day period before or after each vaccine dose.

 -  Treatment with nephrotoxic drugs or competitors of renal excretion within 2 months
 prior to Screening or the expectation that patient will receive any of these during
 the course of the study. TAF/TDF given as NA therapy is allowed.

 -  Concurrently participating in another clinical study, at any time during the study
 period, in which the patient has been or will be exposed to an investigational or a
 non-investigational vaccine/product (pharmaceutical product or device).

 -  Medical history of cirrhosis.

 -  Medical history of hepatic decompensation.

 -  Planned for liver transplantation or previous liver transplantation.

 -  Personal or family (first degree) history of autoimmune disease.

 -  Family history of congenital or hereditary immunodeficiency.

 -  History of any reaction or hypersensitivity likely to be exacerbated by any component
 of the vaccines.

 -  Evidence of Hepatitis C Virus and hepatitis D Virus infection. History of acute
 hepatitis A and acute hepatitis E is not an exclusion criterion.

 -  Suspicion of or confirmed Hepatocellular Carcinoma or any other liver cancer in
 medical history or at Screening:

 -  Suspicious foci at liver imaging exam

 -  Elevated α-fetoprotein > 50 ng/mL.

 -  Documented evidence of other currently active cause of hepatitis.

 -  Hematology and biochemistry parameters outside normal clinical range at Screening:

 Biochemistry:

 -  Glomerular filtration rate < 60 mL/min

 -  Bilirubin > 27.5 µmol/L unless it is considered as clinically not significant by the
 Investigator or the diagnosis of Gilbert Syndrome has been established and confirmed
 by the Investigator

 -  (Gamma Glutamyl Transferase) GGT > 65 U/L for males or GGT > 45 U/L for females*

 -  ALT > 48 U/L

 -  Aspartate Aminotransferase > 42 U/L*

 -  Alkaline Phosphatase > 125 U/L*

 Hematology:

 -  Hemoglobin < 12.0 g/dL (for females) or < 13.5 g/dL (for males)*

 -  Red blood cell count < 3.9 x 10^6 cells/mm^3 (females) or < 4.4 x 10^6 cells/mm^3
 (males)*

 -  White blood cell count < 3,500 cells/mm^3 or > 12,000 cells/mm^3*

 -  Platelets < 140,000 cells/mm^3

 -  INR > 1.32 (i.e. 1.1 x ULN) *unless it is considered as clinically not significant by
 the Investigator

 -  Known diabetes Type I.

 -  Body Mass Index > 35 kg/m^2 at Screening.

 -  Any serious or active medical or psychiatric illnesses other than chronic
 hepatitis B which, in the opinion of the investigator, would interfere with
 patient treatment, assessment or compliance with the protocol. This would include
 any uncontrolled clinically significant renal, cardiac, pulmonary, vascular,
 neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease),
 immunodeficiency disorders or cancer.

 -  History of or current drug abuse and/or excess of alcohol consumption as defined
 per local guidelines.

 -  Human Immunodeficiency Virus-positive patient.

 -  Pregnant or lactating female.

 -  Female planning to become pregnant or planning to discontinue contraceptive
 precautions in the period starting from the Screening Visit up to 12 weeks
 post-last vaccination visit.

 -  Fever and or acute minor illness (such as mild diarrhea, mild upper respiratory
 infection) may be enrolled for Screening at the discretion of the investigator,
 provided that the condition is resolved at the time of vaccination.